@article{8a015860943a41859600b38868afb5bd,
title = "Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation",
abstract = "Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.",
author = "J Hislop and Z Quayyum and A Elders and C Fraser and D Jenkinson and G Mowatt and P Sharma and L Vale and R Petty",
year = "2011",
doi = "10.3310/hta15250",
language = "English",
volume = "15",
pages = "1--178",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "National Co-ordinating Centre for HTA",
number = "25",
}